Search

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

Sickle Cell Disease: From Research to Clinical Management

Elevate your expertise and impact patient care by joining the EHA's pilot preceptorship on Sickle Cell Disease, designed for early-career hematology specialists, clinicians, lab technicians, and pathologists.

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

Trial membership

Are you interested in connecting with EHA and our vibrant community, but you're not yet ready to apply for membership?

By becoming an EHA guest, you can enjoy 60 days of free access to:

The European Hematology Curriculum
Select courses on EHA Campus
You'll…

Read more

Open Access: the ‘Plan S’

 

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.

Read more